About this episode

This episode discusses two randomized clinical trials on the treatment of cephalosporin-resistant Enterobacterales bacteremia presented at ESCMID Global.

Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Trials Run’ session at ESCMID Global, where two randomized, clinical trials are presented in great depth. This year, both trials focused on treatment of cephalosporin-resistant Enterobacterales bacteremia. Listen to the authors describe why they performed these trials, results, and implications for clinical practice. References: 1. Paul, M., & Rodríguez-Baño, J. (2026, April 20). The trial run: treatment of ESBL bacteraemia [LW1] - off to never-never land . [Presentation]. ESCMID Global 2026, Munich, Germany. ESCMID Global Virtual Platform . 2. Bitterman R, Koppel F, Mussini C, et al. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open . 2021;11(2):e040210. Published 2021 Feb 8. doi:10.1136/bmjopen-2020-040210 3. Marín-Candón A, Rosso-Fernández CM, Bustos de Godoy N, et al. Temocillin…

Explore listener stats, chart rankings, contacts and more on the Breakpoints podcast page.